These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11848612)

  • 1. HER-2/neu-Positive breast carcinoma: molecular concomitants by proteomic analysis and their therapeutic implications.
    Brown RE
    Ann Clin Lab Sci; 2002; 32(1):12-21. PubMed ID: 11848612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
    Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry: a new approach for the molecular profiling of breast cancer.
    Lostumbo A; Mehta D; Setty S; Nunez R
    Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
    Katdare M; Osborne M; Telang NT
    Int J Oncol; 2002 Oct; 21(4):809-15. PubMed ID: 12239620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
    Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
    Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells.
    Masuda M; Suzui M; Lim JT; Weinstein IB
    Clin Cancer Res; 2003 Aug; 9(9):3486-91. PubMed ID: 12960141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early nuclear alterations and immunohistochemical expression of Ki-67, Erb-B2, vascular endothelial growth factor (VEGF), transforming growth factor (TGF-beta1) and integrine-linked kinase (ILK) two days after tamoxifen in breast carcinoma.
    Morena AM; Oshima CT; Gebrim LH; Egami MI; Silva MR; Segreto RA; Giannotti Filho O; Teixeira VP; Segreto HR
    Neoplasma; 2004; 51(6):481-6. PubMed ID: 15640959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines.
    Liu L; Gudas LJ
    J Cell Physiol; 2002 Nov; 193(2):244-52. PubMed ID: 12385002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer.
    Lanza-Jacoby S; Burd R; Rosato FE; McGuire K; Little J; Nougbilly N; Miller S
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6161-9. PubMed ID: 17062693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
    Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
    Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of anticancer drugs on production of transforming growth factor and expression of p53 AND Bcl-2 proteins by MCF-7 and T47D cell lines of human breast carcinoma.
    Stoika RS; Yakymovych IA; Kashchak NI; Boyko MM; Korynevska AV; Klyuchyvska OY; Shafranska GI; Yakymovych MY; Zhylchuk VY; Kudryavets YY; Vorontsova AL
    Exp Oncol; 2008 Mar; 30(1):35-41. PubMed ID: 18438339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
    Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
    Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.